The FH Foundation is a patient-centered, research and advocacy organization dedicated to improving early diagnosis and encouraging proactive care of familial hypercholesterolemia

calendar of events
View All

Upcoming Events

  1. 2018 National Lipid Association (NLA) Scientific Sessions Las Vegas

    2018 National Lipid Association (NLA) Scientific Sessions Las Vegas

    View Event
    Apr
    26
  2. May
    4
  3. ISPOR 23rd Annual International Meeting

    ISPOR 23rd Annual International Meeting

    View Event
    May
    19
latest news
View All
The FH Foundation Applauds UnitedHealthcare for Simplifying Prior Authorization for PCSK9 Inhibitors for Individuals with Familial Hypercholesterolemia
18 April, 2018 Comments

Today, The FH Foundation, is pleased to recognize UnitedHealthcare for streamlining its prior authorization process and expanding access to PCSK9 inhibitors for familial hypercholesterolemia (FH). These changes are making it easier and faster for doctors and patients who qualify to get access to these important therapies.

UnitedHealthcare … VIEW ARTICLE

BioReport Podcast Highlights Need to Diagnose and Treat FH
13 April, 2018 Comments

Katherine Wilemon, founder and CEO of the FH Foundation, talked with Daniel Levine of The Bio Report podcast, about familial hypercholesterolemia (FH). The episode highlights how FH is an  invisible condition that causes high LDL-C cholesterol and increases the risk for early heart disease. Unfortunately, too may individuals … VIEW ARTICLE

ODYSSEY Outcomes Results Promising for Individuals with Familial Hypercholesterolemia
10 March, 2018 Comments

The results of the ODYSSEY Outcomes trial of Alirocumab (Praluent) were presented today at the American College of Cardiology Scientific sessions. Alirocumab is an injectable antibody PCSK9 inhibitor that has been shown to significantly reduce LDL-cholesterol levels in prior trials.
ODYSSEY Background
ODYSSEY was … VIEW ARTICLE